Market revenue in 2023 | USD 318.7 million |
Market revenue in 2030 | USD 345.6 million |
Growth rate | 1.2% (CAGR from 2023 to 2030) |
Largest segment | Antacids |
Fastest growing segment | H2 Receptor Blockers |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Antacids, H2 Receptor Blockers, Proton Pump Inhibitors (PPIs), Pro-kinetic agents |
Key market players worldwide | AstraZeneca PLC, Eisai Co Ltd, GSK PLC, Takeda Pharmaceutical Co Ltd, Ironwood Pharmaceuticals Inc Class A, Johnson & Johnson, Phathom Pharmaceuticals Inc Ordinary shares |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to gastroesophageal reflux disease therapeutics market will help companies and investors design strategic landscapes.
Antacids was the largest segment with a revenue share of 56.64% in 2023. Horizon Databook has segmented the Japan gastroesophageal reflux disease therapeutics market based on antacids, h2 receptor blockers, proton pump inhibitors (ppis), pro-kinetic agents covering the revenue growth of each sub-segment from 2018 to 2030.
Elderly population is highly susceptible to gastric reflux, and Japan has the largest geriatric population. According to an article published in by S. Karger AG in the International Journal of Gastroenterology in 2016.
Acid reflux-related symptoms were reported in 6.6% to 9.8% of population on a monthly basis and a majority of erosive esophagitis patients had mild GERD. More than 50% of these patients suffered from nonerosive reflux disease and erosive esophagitis.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan gastroesophageal reflux disease therapeutics market , including forecasts for subscribers. This country databook contains high-level insights into Japan gastroesophageal reflux disease therapeutics market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account